Gladius Capital Management LP Vir Biotechnology, Inc. Transaction History

Gladius Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$8.6 - $11.9 $32,628 - $45,148	3,794 New	3,794 $38,000
Q3 2023 Oct 10, 2023	BUY	$9.14 - $24.62 $19,294 - $51,972	2,111 New	2,111 $20,000
Q1 2023 Dec 18, 2023	SELL	$22.26 - $30.85 $19,922 - $27,610	-895 Reduced 42.4%	1,216 $28,000
Q1 2023 May 09, 2023	SELL	$22.26 - $30.85 $3,294 - $4,565	-148 Reduced 10.85%	1,216 $29,000
Q4 2022 Dec 18, 2023	SELL	$19.96 - $28.22 $14,910 - $21,080	-747 Reduced 35.39%	1,364 $34,000
Q4 2022 Feb 02, 2023	SELL	$19.96 - $28.22 $3,293 - $4,656	-165 Reduced 10.79%	1,364 $35,000
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $27,919 - $47,551	1,529 New	1,529 $30,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.